調査レポート | • レポートコード：GIR-2104Z06872 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥494,160 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥741,240 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥988,320 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、血友病治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。血友病治療の種類別市場規模（オンデマンド、予防）、用途別市場規模（補充療法、ITI療法、遺伝子療法）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・血友病治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：CSL Behring、Baxalta、Pfizer Inc、BioMarin、Bayer Healthcare、Biogen、Novo Nordisk、Roche、Takeda ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：オンデマンド、予防 ・用途別分析2016年-2026年：補充療法、ITI療法、遺伝子療法 ・血友病治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・血友病治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・血友病治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・血友病治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・血友病治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Hemophilia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Hemophilia Treatment size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Hemophilia Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Hemophilia Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
On-demand
Prophylaxis
Market segment by Application, can be divided into
Replacement Therapy
ITI Therapy
Gene Therapy
Market segment by players, this report covers
CSL Behring
Baxalta
Pfizer Inc
BioMarin
Bayer Healthcare
Biogen
Novo Nordisk
Roche
Takeda
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Hemophilia Treatment
1.2 Classification of Hemophilia Treatment by Type
1.2.1 Overview: Global Hemophilia Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Hemophilia Treatment Revenue Market Share by Type in 2020
1.2.3 On-demand
1.2.4 Prophylaxis
1.3 Global Hemophilia Treatment Market by Application
1.3.1 Overview: Global Hemophilia Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Replacement Therapy
1.3.3 ITI Therapy
1.3.4 Gene Therapy
1.4 Global Hemophilia Treatment Market Size & Forecast
1.5 Global Hemophilia Treatment Market Size and Forecast by Region
1.5.1 Global Hemophilia Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Hemophilia Treatment Market Size by Region, (2016-2021)
1.5.3 North America Hemophilia Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Hemophilia Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Hemophilia Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Hemophilia Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Hemophilia Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Hemophilia Treatment Market Drivers
1.6.2 Hemophilia Treatment Market Restraints
1.6.3 Hemophilia Treatment Trends Analysis
2 Company Profiles
2.1 CSL Behring
2.1.1 CSL Behring Details
2.1.2 CSL Behring Major Business
2.1.3 CSL Behring Hemophilia Treatment Product and Solutions
2.1.4 CSL Behring Hemophilia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 CSL Behring Recent Developments and Future Plans
2.2 Baxalta
2.2.1 Baxalta Details
2.2.2 Baxalta Major Business
2.2.3 Baxalta Hemophilia Treatment Product and Solutions
2.2.4 Baxalta Hemophilia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Baxalta Recent Developments and Future Plans
2.3 Pfizer Inc
2.3.1 Pfizer Inc Details
2.3.2 Pfizer Inc Major Business
2.3.3 Pfizer Inc Hemophilia Treatment Product and Solutions
2.3.4 Pfizer Inc Hemophilia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Pfizer Inc Recent Developments and Future Plans
2.4 BioMarin
2.4.1 BioMarin Details
2.4.2 BioMarin Major Business
2.4.3 BioMarin Hemophilia Treatment Product and Solutions
2.4.4 BioMarin Hemophilia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 BioMarin Recent Developments and Future Plans
2.5 Bayer Healthcare
2.5.1 Bayer Healthcare Details
2.5.2 Bayer Healthcare Major Business
2.5.3 Bayer Healthcare Hemophilia Treatment Product and Solutions
2.5.4 Bayer Healthcare Hemophilia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Bayer Healthcare Recent Developments and Future Plans
2.6 Biogen
2.6.1 Biogen Details
2.6.2 Biogen Major Business
2.6.3 Biogen Hemophilia Treatment Product and Solutions
2.6.4 Biogen Hemophilia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Biogen Recent Developments and Future Plans
2.7 Novo Nordisk
2.7.1 Novo Nordisk Details
2.7.2 Novo Nordisk Major Business
2.7.3 Novo Nordisk Hemophilia Treatment Product and Solutions
2.7.4 Novo Nordisk Hemophilia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Novo Nordisk Recent Developments and Future Plans
2.8 Roche
2.8.1 Roche Details
2.8.2 Roche Major Business
2.8.3 Roche Hemophilia Treatment Product and Solutions
2.8.4 Roche Hemophilia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Roche Recent Developments and Future Plans
2.9 Takeda
2.9.1 Takeda Details
2.9.2 Takeda Major Business
2.9.3 Takeda Hemophilia Treatment Product and Solutions
2.9.4 Takeda Hemophilia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Takeda Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Hemophilia Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Hemophilia Treatment Players Market Share
3.2.2 Top 10 Hemophilia Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Hemophilia Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Hemophilia Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Hemophilia Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Hemophilia Treatment Revenue Market Share by Application (2016-2021)
5.2 Hemophilia Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Hemophilia Treatment Revenue by Type (2016-2026)
6.2 North America Hemophilia Treatment Revenue by Application (2016-2026)
6.3 North America Hemophilia Treatment Market Size by Country
6.3.1 North America Hemophilia Treatment Revenue by Country (2016-2026)
6.3.2 United States Hemophilia Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Hemophilia Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Hemophilia Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Hemophilia Treatment Revenue by Type (2016-2026)
7.2 Europe Hemophilia Treatment Revenue by Application (2016-2026)
7.3 Europe Hemophilia Treatment Market Size by Country
7.3.1 Europe Hemophilia Treatment Revenue by Country (2016-2026)
7.3.2 Germany Hemophilia Treatment Market Size and Forecast (2016-2026)
7.3.3 France Hemophilia Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Hemophilia Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Hemophilia Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Hemophilia Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Hemophilia Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Hemophilia Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Hemophilia Treatment Market Size by Region
8.3.1 Asia-Pacific Hemophilia Treatment Revenue by Region (2016-2026)
8.3.2 China Hemophilia Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Hemophilia Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Hemophilia Treatment Market Size and Forecast (2016-2026)
8.3.5 India Hemophilia Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Hemophilia Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Hemophilia Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Hemophilia Treatment Revenue by Type (2016-2026)
9.2 South America Hemophilia Treatment Revenue by Application (2016-2026)
9.3 South America Hemophilia Treatment Market Size by Country
9.3.1 South America Hemophilia Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Hemophilia Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Hemophilia Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Hemophilia Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Hemophilia Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Hemophilia Treatment Market Size by Country
10.3.1 Middle East & Africa Hemophilia Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Hemophilia Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Hemophilia Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Hemophilia Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Hemophilia Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Hemophilia Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Hemophilia Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Hemophilia Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Hemophilia Treatment Revenue Market Share by Region (2021-2026)
Table 6. CSL Behring Corporate Information, Head Office, and Major Competitors
Table 7. CSL Behring Major Business
Table 8. CSL Behring Hemophilia Treatment Product and Solutions
Table 9. CSL Behring Hemophilia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Baxalta Corporate Information, Head Office, and Major Competitors
Table 11. Baxalta Major Business
Table 12. Baxalta Hemophilia Treatment Product and Solutions
Table 13. Baxalta Hemophilia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Pfizer Inc Corporate Information, Head Office, and Major Competitors
Table 15. Pfizer Inc Major Business
Table 16. Pfizer Inc Hemophilia Treatment Product and Solutions
Table 17. Pfizer Inc Hemophilia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. BioMarin Corporate Information, Head Office, and Major Competitors
Table 19. BioMarin Major Business
Table 20. BioMarin Hemophilia Treatment Product and Solutions
Table 21. BioMarin Hemophilia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Bayer Healthcare Corporate Information, Head Office, and Major Competitors
Table 23. Bayer Healthcare Major Business
Table 24. Bayer Healthcare Hemophilia Treatment Product and Solutions
Table 25. Bayer Healthcare Hemophilia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Biogen Corporate Information, Head Office, and Major Competitors
Table 27. Biogen Major Business
Table 28. Biogen Hemophilia Treatment Product and Solutions
Table 29. Biogen Hemophilia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 31. Novo Nordisk Major Business
Table 32. Novo Nordisk Hemophilia Treatment Product and Solutions
Table 33. Novo Nordisk Hemophilia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Roche Corporate Information, Head Office, and Major Competitors
Table 35. Roche Major Business
Table 36. Roche Hemophilia Treatment Product and Solutions
Table 37. Roche Hemophilia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Takeda Corporate Information, Head Office, and Major Competitors
Table 39. Takeda Major Business
Table 40. Takeda Hemophilia Treatment Product and Solutions
Table 41. Takeda Hemophilia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Global Hemophilia Treatment Revenue (USD Million) by Players (2019-2021)
Table 43. Global Hemophilia Treatment Revenue Share by Players (2019-2021)
Table 44. Breakdown of Hemophilia Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Hemophilia Treatment Players Head Office, Products and Services Provided
Table 46. Hemophilia Treatment Mergers & Acquisitions in the Past Five Years
Table 47. Hemophilia Treatment New Entrants and Expansion Plans
Table 48. Global Hemophilia Treatment Revenue (USD Million) by Type (2016-2021)
Table 49. Global Hemophilia Treatment Revenue Share by Type (2016-2021)
Table 50. Global Hemophilia Treatment Revenue Forecast by Type (2021-2026)
Table 51. Global Hemophilia Treatment Revenue by Application (2016-2021)
Table 52. Global Hemophilia Treatment Revenue Forecast by Application (2021-2026)
Table 53. North America Hemophilia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 54. North America Hemophilia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 55. North America Hemophilia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 56. North America Hemophilia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 57. North America Hemophilia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 58. North America Hemophilia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 59. Europe Hemophilia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 60. Europe Hemophilia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 61. Europe Hemophilia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 62. Europe Hemophilia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 63. Europe Hemophilia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 64. Europe Hemophilia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 65. Asia-Pacific Hemophilia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 66. Asia-Pacific Hemophilia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 67. Asia-Pacific Hemophilia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 68. Asia-Pacific Hemophilia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 69. Asia-Pacific Hemophilia Treatment Revenue by Region (2016-2021) & (USD Million)
Table 70. Asia-Pacific Hemophilia Treatment Revenue by Region (2021-2026) & (USD Million)
Table 71. South America Hemophilia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 72. South America Hemophilia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 73. South America Hemophilia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 74. South America Hemophilia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 75. South America Hemophilia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 76. South America Hemophilia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 77. Middle East & Africa Hemophilia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 78. Middle East & Africa Hemophilia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 79. Middle East & Africa Hemophilia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 80. Middle East & Africa Hemophilia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 81. Middle East & Africa Hemophilia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 82. Middle East & Africa Hemophilia Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Hemophilia Treatment Picture
Figure 2. Global Hemophilia Treatment Revenue Market Share by Type in 2020
Figure 3. On-demand
Figure 4. Prophylaxis
Figure 5. Hemophilia Treatment Revenue Market Share by Application in 2020
Figure 6. Replacement Therapy Picture
Figure 7. ITI Therapy Picture
Figure 8. Gene Therapy Picture
Figure 9. Global Hemophilia Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Hemophilia Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Hemophilia Treatment Revenue Market Share by Region (2016-2026)
Figure 12. Global Hemophilia Treatment Revenue Market Share by Region in 2020
Figure 13. North America Hemophilia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Hemophilia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Hemophilia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Hemophilia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Hemophilia Treatment Market Drivers
Figure 18. Hemophilia Treatment Market Restraints
Figure 19. Hemophilia Treatment Market Trends
Figure 20. CSL Behring Recent Developments and Future Plans
Figure 21. Baxalta Recent Developments and Future Plans
Figure 22. Pfizer Inc Recent Developments and Future Plans
Figure 23. BioMarin Recent Developments and Future Plans
Figure 24. Bayer Healthcare Recent Developments and Future Plans
Figure 25. Biogen Recent Developments and Future Plans
Figure 26. Novo Nordisk Recent Developments and Future Plans
Figure 27. Roche Recent Developments and Future Plans
Figure 28. Takeda Recent Developments and Future Plans
Figure 30. Global Hemophilia Treatment Revenue Share by Players in 2020
Figure 31. Hemophilia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 32. Global Top 3 Players Hemophilia Treatment Revenue Market Share in 2020
Figure 33. Global Top 10 Players Hemophilia Treatment Revenue Market Share in 2020
Figure 34. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 35. Global Hemophilia Treatment Revenue Share by Type in 2020
Figure 36. Global Hemophilia Treatment Market Share Forecast by Type (2021-2026)
Figure 37. Global Hemophilia Treatment Revenue Share by Application in 2020
Figure 38. Global Hemophilia Treatment Market Share Forecast by Application (2021-2026)
Figure 39. North America Hemophilia Treatment Sales Market Share by Type (2016-2026)
Figure 40. North America Hemophilia Treatment Sales Market Share by Application (2016-2026)
Figure 41. North America Hemophilia Treatment Revenue Market Share by Country (2016-2026)
Figure 42. United States Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Canada Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Mexico Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Europe Hemophilia Treatment Sales Market Share by Type (2016-2026)
Figure 46. Europe Hemophilia Treatment Sales Market Share by Application (2016-2026)
Figure 47. Europe Hemophilia Treatment Revenue Market Share by Country (2016-2026)
Figure 48. Germany Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. France Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. United Kingdom Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Russia Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Italy Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Asia-Pacific Hemophilia Treatment Sales Market Share by Type (2016-2026)
Figure 54. Asia-Pacific Hemophilia Treatment Sales Market Share by Application (2016-2026)
Figure 55. Asia-Pacific Hemophilia Treatment Revenue Market Share by Region (2016-2026)
Figure 56. China Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Japan Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. South Korea Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. India Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Southeast Asia Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Australia Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South America Hemophilia Treatment Sales Market Share by Type (2016-2026)
Figure 63. South America Hemophilia Treatment Sales Market Share by Application (2016-2026)
Figure 64. South America Hemophilia Treatment Revenue Market Share by Country (2016-2026)
Figure 65. Brazil Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Argentina Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Middle East and Africa Hemophilia Treatment Sales Market Share by Type (2016-2026)
Figure 68. Middle East and Africa Hemophilia Treatment Sales Market Share by Application (2016-2026)
Figure 69. Middle East and Africa Hemophilia Treatment Revenue Market Share by Country (2016-2026)
Figure 70. Turkey Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Saudi Arabia Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. UAE Hemophilia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Methodology
Figure 74. Research Process and Data Source
世界の後天性血友病A治療市場規模・現状・予測（2021年-2027年） ELOCTATE, a therapy regimen for the treatment of hemophilia A that uses Fc Fusion to keep Factor VIII circulating in your bloodstream longer. Market Analysis and Insights: Global Acquired hemophilia A Treatment Market The global Acquired hemophilia A Treatment market size is projected to reach US$ X…- 世界の血友病A・B組換え因子補充療法市場規模・現状・予測（2021年-2027年） Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptom…
- 世界の血友病遺伝子治療市場規模・現状・予測（2021年-2027年） Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot an…
- 世界の血友病治療市場規模・現状・予測（2021年-2027年） Hemophilia is a rare, inherited disorder in which blood doesn’t clot normally due to the lack of sufficient blood clotting factor. Clotting factor is a protein required for blood clotting to occur normally. These proteins work with platelets i.e. small blood cell fragments that form in the bone marr…
- 世界の希少血友病因子市場 2021：企業別、地域別、種類・用途別 The Rare Hemophilia Factors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…